

VAKSIMUNE® IBD D

PROTECTION AGAINST INFECTIOUS BURSAL DISEASE



VAKSIMUNE® IBD D

Challenges & Our Commitment:

Infectious Bursal Disease (IBD) is an acute, highly contagious infection primarily affecting young chickens. Caused by the infectious bursal disease virus (IBDV), the virus targets the lymphoid tissues of the bursa of Fabricius, leading to immunosup-pression. The severity of infection varies depending on the virus strain, with most young chickens being highly susceptible to the disease, which poses significant challenges to the poultry industry due to its immunosuppressive effects (Kaufer and Weiss 1980: Luketr and Saif 2013: Allan et al. 1972).

Vaksimune IBD D offers a balanced approach to IBD vaccination. As an intermediate plus vaccine, it combines the robust protective power of an intermediate plus vaccine with the safety profile of an intermediate vaccine. This ensures effective immunity without significant immunosuppression or bursal damage, minimizing post-vaccinal reactions and maintaining overall flock health and performance.

Features:

VAKSIMUNE® IBD D is a freeze dried modified live virus, each dose contains:

Infectious Bursal Disease LZD 228 Strain > 1020 EID.

VAKSIMUNE®IBD D is propagated in embryonated Specific Pathogen Free (SPF) chicken eggs. Maternal Antibody Breakthrough is 300.



Vaccination Strategy: Broiler/Breeder/Layer:

1st Vaccination: 11-14 Days of Age 2nd Vaccination: 18-21 Days of Age

Vaccine Administration:

Vaccine can be administered via oral drop, drinking water

Packing size:

Available in 1000 & 2000 Doses

VAKSIMUNE® IBD D Benefits



Balanced Protection With Minimal Reaction

Vaksimune IBD D, containing the LZD228 strain, provides strong intermediate-plus protection with low postvaccinal reactions (PVR). This minimizes bursal damage, ensuring effective IBD protection while maintaining flock health.



Faster Immune Response

Vaksimune IBD D breaks through maternal antibodies (MDA) early, ensuring faster active immunity in young chickens, which is crucial for preventing IBD outbreaks and reducing production losses and mortality.




Maintains Immunecompetence

Vaksimune IBD D does not interfere with the bird's ability to develop immune competence, allowing them to maintain a healthy immune system even when vaccinated for multiple diseases.



Serology Titer Comparison in Broiler Chickens

A trial on 1500 birds compared the antibody responses of Vaksimune IBD D and another live attenuated vaccine, both administered on days 10 and 15. Blood samples were analyzed using ELISA on days 1, 14, 18, 21, and 28. The results showed that Vaksimune IBD D outperformed the other vaccine in both speed and antibody levels, with a GMT of 1410 on day 21 and 1990 on day 28, compared to 820 and 1205 for the other vaccine.



Evaluation of Vaksimune IBD D's Effect on Immune Response in Birds

A study on 1000 birds evaluated the impact of Vaksimune IBD D on their immune competence, particularly their ability to respond to Newcastle Disease (ND). Results showed that Vaksimune IBD D did not hinder the immune response, as ND titers began to rise after day 21, indicating a strong and timely immunity. The steady increase in ND HI titers throughout the study further supports this conclusion.

